Clinical trials: Hepatitis; Epidemic
Hepatitis C
Hepatitis C-Video vs. Brochure Education Delivery
The purpose of this study is to determine the most effective way to give patients information regarding hepatitis C virus infection.
- Trial name
- NCT04204447
- Testing
- Hepatitis C Educational Brochure, Hepatitis C Educational Video
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- State University of New York at Buffalo
Hepatitis B, Chronic
Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B
For HBeAg(+) patients, interferon is used for 12 weeks. On 12th week of treatment, If HBV DNA is undetectable (<1000 copies/ml), interferon is continued alone for one year.
- Trial name
- NCT00860626
- Testing
- interferon α plus nucleoside analogue, interferon α
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
HCV Infection
Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)
The overall study design includes two parts, Part A and Part B. Part A evaluated ANA773 following oral administration to healthy volunteers. A total of 40 evaluable healthy volunteers were enrolled in Part A of the study.
- Trial name
- NCT01211626
- Testing
- ANA773
- Where
- 3 sites in Netherlands
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action Antivirals
The purpose of this study is to evaluate the evolution of liver injury with fibrosis data obtained using non-invasive serological markers in patients who achieved SVR after treatment with direct-acting antivirals.
- Trial name
- Hepatitis (NCT05062408)
- Where
- Spain
- Volunteers
- 321 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Hepatitis C
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
The purpose of this study is to investigate the efficacy of a treatment with TMC435 in combination with peginterferon alfa-2a and ribavirin in patients who did not clear their hepatitis C infection with peginterferon alfa-2a and…
- Trial name
- NCT01323244
- Testing
- TMC435
- Where
- 72 sites in United States, Argentina and 20 more
- Volunteers
- 142 people
- Sponsor
- Janssen R&D Ireland
Hepatitis B, Chronic
A Non-invasive Model to Predict Antiviral Therapy in Gray Zone of Chronic Hepatitis B
Establishment and validation of the non-invasive model to predict antiviral therapy in the gray zone of chronic hepatitis B
- Trial name
- NCT06041022
- Testing
- Exposure factors
- Volunteers
- 1,000 people
- Sponsor
- Qilu Hospital of Shandong University
Hepatitis B, Liver Fibrosis
Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis
Compared to TDF, peginterferon alfa 2a may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients.
- Trial name
- NCT03957629
- Testing
- Tenofovir Disoproxil Fumarate, PEG-Interferon alfa 2a
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B Reactivation
TDF and Entekavir - Hepatitis B Reactivation
This is a non-interventional retrospective multi-center study for the patients received Entekavir or TDF for Hepatitis B prophylaxis.
- Trial name
- NCT06049602
- Where
- Turkey (Türkiye)
- Volunteers
- 10,000 people
- Sponsor
- Viral Hepatitis Society
Hepatitis B, Chronic
Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients
Previous studies indicated that Granulocyte Macrophage-colony Stimulating Factor (GM-CSF) could improve survival rate in patients with acute liver failure and obtain higher HBsAg seroconversion rate when in combination with…
- Trial name
- NCT03164889
- Testing
- Granulocyte Macrophage-colony Stimulating Factor, Entecavir
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing 302 Hospital
Hepatitis B, Chronic, Hepatic Steatosis
Aerobic Exercise Training in Patients With Chronic Hepatitis B and Hepatic Steatosis
This study is a randomised, controlled, unblinded, clinical intervention trial consisting of 12 weeks of aerobic exercise training.
- Trial name
- FitLiver (NCT05265026)
- Testing
- High Intensity Interval Training
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Chronic Hepatitis c
'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
Objective: To coordinate active tracing of chronic hepatitis C patients lost to follow-up to inform them about there disease severity and treatment options.
- Trial name
- Track&Trace (NCT03088917)
- Where
- Netherlands
- Volunteers
- 106 people
- Sponsor
- Radboud University Medical Center
Hepatitis C, Thalassemia
Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection
Antiviral treatment of HCV in thalassemia has raised concerns of ribavirin-induced hemolysis and increased iron loading. Blood Transfusion in Thalassemic patients are a known high risk for acquiring hepatitis C.
- Trial name
- NCT00707850
- Testing
- PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
- Where
- Iran
- Volunteers
- 300 people
- Sponsor
- Baqiyatallah Medical Sciences University
HCV Infection
Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection
This study is to determine the antiviral efficacy of sofosbuvir (SOF)/ledipasvir (LDV) fixed-dose combination (FDC) with and without ribavirin (RBV), and to evaluate the safety and tolerability of each regimen as assessed by…
- Trial name
- NCT01965535
- Testing
- LDV/SOF, RBV
- Where
- 19 sites in France
- Volunteers
- 155 people
- Sponsor
- Gilead Sciences
Hepatitis B
HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers
Antibodies are the primary mediators of the protection against infection provided by vaccination. Antibodies become most powerful after the B cells that produce them undergo an evolutionary process called affinity maturation, in…
- Trial name
- NCT05272735
- Testing
- Hepatitis B Vaccine (Recombinant)
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV Infection, Hepatitis C
A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects
The purpose of this study is to determine whether a simplified lopinavir/ritonavir-based therapy will continue to keep the viral load at very low levels after initial treatment with a combination of Kaletra (lopinavir/ritonavir)…
- Trial name
- NCT00121017
- Testing
- Kaletra (lopinavir/ritonavir), Sustiva (efavirenz), Truvada (emtricitabine/tenofovir disoproxil fumarate)
- Volunteers
- 200 people
- Sponsor
- Abbott
Chronic Hepatitis C Infection, Hepatitis C
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
The purpose of this study is to evaluate the antiviral activity, safety, and pharmacokinetics of ABT-450 with ritonavir (ABT-450/r) dosed in combination with ABT-333 (also known as dasabuvir) and ribavirin (RBV) in…
- Conditions
- Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C Virus
- Trial name
- NCT01306617
- Testing
- ABT-450, ABT-333, ribavirin
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HCV Infection
Chronic Hepatitis C in Chronic Hemodialysis Recipients - An Observational Study
This is an observational study of cases of chronic hepatitis C and negative HCV controls in adults receiving chronic hemodialysis at the National Renal Health Center (NRHC) -EsSalud in Lima - Peru.The NRHC provides specialized…
- Trial name
- (CHINCHERO) (NCT03461250)
- Testing
- HCV serology
- Volunteers
- 293 people
- Sponsor
- Asociacion para el Estudio del Higado
Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of
HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy
Chronic hepatitis C virus (HCV) infection remains a health burden in people living with human immunodeficiency virus (HIV). Interferon (IFN)-based therapy is the treatment of choice for HCV infection for HIV coinfected patients…
- Conditions
- Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus (HIV) Coinfection
- Trial name
- NCT04768517
- Where
- 7 sites in Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
Liver Diseases, Hepatitis, Chronic
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
The purpose of this study is to collect epidemiological data in children and adolescents with chronic hepatitis B(CHB), in particular data on the prevalence of HBeAg positive disease with associated ALT levels , active HBeAg…
- Conditions
- Liver Diseases, Hepatitis, Chronic, Hepatitis, Viral, Human, Hepatitis
- Trial name
- EPIC B (NCT01163240)
- Where
- 86 sites in United States, Argentina and 16 more
- Volunteers
- 1,640 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C
Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs
Neuropsychiatric adverse effects of direct acting antiviral drugs, especially Sofosbuvir and Daclatasvir combination therapy (with or without ribavirin) in patients with chronic hepatitis C , genotype four (the predominant…
- Trial name
- NCT03268317
- Volunteers
- 100 people
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.